Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 Add-on to Salmeterol/Fluticasone in COPD
NCT01757015Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Apr 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Planned start Apr 2013; status: withdrawn.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01757015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01757015.